ASCO: Merck clamps down on lung cancer lead with another solo Keytruda win

3rd June 2018 Uncategorised 0

Merck’s Keytruda already boasts a standalone approval for lung cancer patients who haven’t been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it could soon reach beyond that group, thanks to new data presented Sunday.

More: ASCO: Merck clamps down on lung cancer lead with another solo Keytruda win
Source: fierce